artivion inc. - AORT
AORT
Close Chg Chg %
23.42 0.72 3.07%
Closed Market
24.14
+0.72 (3.07%)
Volume: 366.18K
Last Updated:
Mar 14, 2025, 3:59 PM EDT
Company Overview: artivion inc. - AORT
AORT Key Data
| Open $23.55 | Day Range 23.55 - 24.18 |
| 52 Week Range 19.11 - 32.33 | Market Cap $984.76M |
| Shares Outstanding 42.05M | Public Float 39.40M |
| Beta 1.79 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.32 |
| Yield 0.00% | Dividend $0.03 |
| EX-DIVIDEND DATE Dec 9, 2015 | SHORT INTEREST N/A |
| AVERAGE VOLUME 593.44K |
AORT Performance
| 1 Week | -3.14% | ||
| 1 Month | -22.09% | ||
| 3 Months | -19.05% | ||
| 1 Year | 18.58% | ||
| 5 Years | 7.48% |
AORT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
6
Full Ratings ➔
About artivion inc. - AORT
Artivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.
AORT At a Glance
Artivion, Inc.
1655 Roberts Boulevard NW
Kennesaw, Georgia 30144-3632
| Phone | 1-770-419-3355 | Revenue | 388.54M | |
| Industry | Medical Specialties | Net Income | -13,335,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 9.755% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,600 | |
| View SEC Filings |
AORT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.067 |
| Price to Book Ratio | 4.342 |
| Price to Cash Flow Ratio | 53.585 |
| Enterprise Value to EBITDA | 29.024 |
| Enterprise Value to Sales | 3.861 |
| Total Debt to Enterprise Value | 0.241 |
AORT Efficiency
| Revenue/Employee | 242,835.625 |
| Income Per Employee | -8,334.375 |
| Receivables Turnover | 4.524 |
| Total Asset Turnover | 0.491 |
AORT Liquidity
| Current Ratio | 3.567 |
| Quick Ratio | 2.374 |
| Cash Ratio | 0.80 |
AORT Profitability
| Gross Margin | 59.95 |
| Operating Margin | 7.075 |
| Pretax Margin | -1.934 |
| Net Margin | -3.432 |
| Return on Assets | -1.686 |
| Return on Equity | -4.78 |
| Return on Total Capital | -2.089 |
| Return on Invested Capital | -2.104 |
AORT Capital Structure
| Total Debt to Total Equity | 131.158 |
| Total Debt to Total Capital | 56.74 |
| Total Debt to Total Assets | 45.908 |
| Long-Term Debt to Equity | 129.244 |
| Long-Term Debt to Total Capital | 55.912 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Artivion Inc. - AORT
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 298.84M | 313.79M | 354.00M | 388.54M | |
Sales Growth
| +18.01% | +5.00% | +12.82% | +9.75% | |
Cost of Goods Sold (COGS) incl D&A
| 118.14M | 126.58M | 140.03M | 155.61M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 23.98M | 22.44M | 23.08M | 24.20M | |
Depreciation
| 7.16M | 7.13M | 7.88M | 8.35M | |
Amortization of Intangibles
| 16.82M | 15.31M | 15.20M | 15.86M | |
COGS Growth
| +19.09% | +7.14% | +10.63% | +11.13% | |
Gross Income
| 180.69M | 187.21M | 213.98M | 232.93M | |
Gross Income Growth
| +17.32% | +3.61% | +14.30% | +8.86% | |
Gross Profit Margin
| +60.47% | +59.66% | +60.45% | +59.95% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 174.34M | 172.23M | 199.19M | 205.44M | |
Research & Development
| 35.55M | 38.88M | 28.71M | 28.45M | |
Other SG&A
| 138.80M | 133.35M | 170.48M | 176.99M | |
SGA Growth
| +15.10% | -1.21% | +15.65% | +3.14% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 15.33M | 9.47M | 28.88M | (2.44M) | |
EBIT after Unusual Expense
| (8.98M) | 5.51M | (14.09M) | 29.93M | |
Non Operating Income/Expense
| 10.67M | (2.65M) | 17.89M | (3.08M) | |
Non-Operating Interest Income
| 79.00K | 147.00K | 1.08M | 1.47M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 16.52M | 17.84M | 25.38M | 34.37M | |
Interest Expense Growth
| -1.74% | +7.96% | +42.29% | +35.39% | |
Gross Interest Expense
| 16.52M | 17.84M | 25.38M | 34.37M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (14.83M) | (14.98M) | (21.59M) | (7.51M) | |
Pretax Income Growth
| +13.67% | -1.06% | -44.06% | +65.19% | |
Pretax Margin
| -4.96% | -4.78% | -6.10% | -1.93% | |
Income Tax
| 7.00K | 4.21M | 9.10M | 5.84M | |
Income Tax - Current - Domestic
| 2.45M | 1.97M | 6.58M | 6.69M | |
Income Tax - Current - Foreign
| 3.39M | 3.12M | 3.85M | 665.00K | |
Income Tax - Deferred - Domestic
| (3.11M) | 470.00K | 379.00K | 815.00K | |
Income Tax - Deferred - Foreign
| (2.72M) | (1.35M) | (1.70M) | (2.33M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| 94.00K | 98.00K | 123.00K | 24.00K | |
Consolidated Net Income
| (14.74M) | (19.09M) | (30.57M) | (13.34M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (14.74M) | (19.09M) | (30.57M) | (13.34M) | |
Net Income Growth
| +11.05% | -29.54% | -60.09% | +56.37% | |
Net Margin Growth
| -4.93% | -6.08% | -8.63% | -3.43% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (14.74M) | (19.09M) | (30.57M) | (13.34M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (14.74M) | (19.09M) | (30.57M) | (13.34M) | |
EPS (Basic)
| -0.3781 | -0.477 | -0.7502 | -0.32 | |
EPS (Basic) Growth
| +13.62% | -26.16% | -57.27% | +57.34% | |
Basic Shares Outstanding
| 38.98M | 40.03M | 40.74M | 41.68M | |
EPS (Diluted)
| -0.3781 | -0.477 | -0.7502 | -0.32 | |
EPS (Diluted) Growth
| +13.62% | -26.16% | -57.27% | +57.34% | |
Diluted Shares Outstanding
| 38.98M | 40.03M | 40.74M | 41.68M | |
EBITDA
| 30.33M | 37.43M | 37.86M | 51.69M | |
EBITDA Growth
| -0.24% | +23.41% | +1.17% | +36.52% | |
EBITDA Margin
| +10.15% | +11.93% | +10.70% | +13.30% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 33.167 | |
| Number of Ratings | 6 | Current Quarters Estimate | -0.121 | |
| FY Report Date | 03 / 2025 | Current Year's Estimate | 0.017 | |
| Last Quarter’s Earnings | -0.39 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.32 | Next Fiscal Year Estimate | 0.401 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 6 | 6 | 6 | 6 |
| Mean Estimate | -0.12 | 0.00 | 0.02 | 0.40 |
| High Estimates | -0.03 | 0.04 | 0.19 | 0.53 |
| Low Estimate | -0.22 | -0.02 | -0.22 | 0.12 |
| Coefficient of Variance | -65.18 | 2,600.66 | 823.71 | 36.28 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 6 | 6 | 6 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Artivion Inc. - AORT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Artivion Inc. - AORT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 11, 2025 | James Patrick Mackin President & CEO | 860,368 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.8 per share | 21,337,126.40 |
| Mar 11, 2025 | Marshall S. Stanton SVP, Clinical & MD Affair | 117,483 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | John Elery Davis Chief Commercial Officer | 207,968 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.8 per share | 5,157,606.40 |
| Mar 11, 2025 | Amy D. Horton VP, Chief Accounting Officer | 146,651 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.8 per share | 3,636,944.80 |
| Mar 11, 2025 | Amy D. Horton VP, Chief Accounting Officer | 147,699 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Lance A. Berry Executive VP, CFO | 153,431 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.8 per share | 3,805,088.80 |
| Mar 11, 2025 | Lance A. Berry Executive VP, CFO | 158,340 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | James Patrick Mackin President & CEO | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | James Patrick Mackin President & CEO | 878,107 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | James Patrick Mackin President & CEO | 865,283 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.76 per share | 21,424,407.08 |
| Mar 11, 2025 | John Elery Davis Chief Commercial Officer | 210,586 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Jean F. Holloway SVP, General Counsel | 196,112 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.8 per share | 4,863,577.60 |
| Mar 11, 2025 | Jean F. Holloway SVP, General Counsel | 198,236 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | James Patrick Mackin President & CEO | 935,983 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $21.55 per share | 20,170,433.65 |
| Mar 11, 2025 | Marshall S. Stanton SVP, Clinical & MD Affair | 115,880 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.8 per share | 2,873,824.00 |
| Mar 6, 2025 | Anthony B. Semedo Director | 35,659 | Open market or private purchase of non-derivative security Non-derivative transaction at $25.33 per share | 903,242.47 |
| Mar 6, 2025 | Anthony B. Semedo Director | 600 | Open market or private purchase of non-derivative security Non-derivative transaction at $25.25 per share | 15,150.00 |
| Feb 27, 2025 | Marshall S. Stanton SVP, Clinical & MD Affair | 81,091 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.31 per share | 2,214,595.21 |
| Feb 27, 2025 | Amy D. Horton VP, Chief Accounting Officer | 131,141 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.31 per share | 3,581,460.71 |
| Feb 27, 2025 | Marshall S. Stanton SVP, Clinical & MD Affair | 79,845 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.31 per share | 2,180,566.95 |